SUVEN Suven Life Sciences Q3 FY20 results (Oct–Dec 2019) and concall
The Q3 FY20 earnings call for Suven Life Sciences and Suven Pharmaceuticals highlighted the strategic demerger and future direction of both entities. Suven Life Sciences is focusing on advancing its drug pipeline, with SUVN-502 showing potential for new indications despite a primary endpoint miss, and SUVN-G3031 progressing in Phase II. Suven Pharmaceuticals is expanding its CRAMS business into API and formulations, projecting 20-22% revenue growth for FY20 and a significant CAPEX of Rs. 320 crore. Management also addressed concerns regarding raw material sourcing from China and the funding st
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
